3 June 2016 - NICE has published an appraisal consultation document for pirfenidone (Esbriet) for use by patients with idiopathic pulmonary fibrosis.

NICE has commenced a review of its previous guidance for Esbriet (TA282).  While the appraisal considered several proposed changes by Roche, specifically:

• Expanding the population to include people with a forced vital capacity above 80% predicted
• Removing the recommendation to stop pirfenidone if the disease progresses
• A different patient access scheme for pirfenidone (a higher price)

No change to TA282 are recommended at this time.

For more details, go to: https://www.nice.org.uk/guidance/GID-TAG504/documents/appraisal-consultation-document